What's the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?
Transl Lung Cancer Res
.
2020 Feb;9(1):158-159.
doi: 10.21037/tlcr.2019.12.06.
Authors
Sara Bravaccini
1
,
Paola Ulivi
1
Affiliation
1
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
PMID:
32206564
PMCID:
PMC7082295
DOI:
10.21037/tlcr.2019.12.06
No abstract available